-
12:32:03 AM

DCPH Stock News

05/25/23 5:00 PM
Nasdaq : DCPH
conferencesclinical trial
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023..
RHEA-AI
neutral
04/26/23 7:00 AM
Nasdaq : DCPH
earnings
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023. In connection with the earnings release, Deciphera’ s management team...
RHEA-AI
neutral
03/14/23 5:53 PM
Nasdaq : DCPH
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that QINLOCK ® has been included in the latest National Comprehensive Cancer Network ® Clinical Practice Guidelines in Oncology as a preferred...
RHEA-AI
positive
03/14/23 5:32 PM
Nasdaq : DCPH
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023. Poster Number: 4872 Title:...
RHEA-AI
neutral
03/01/23 7:00 AM
Nasdaq : DCPH
clinical trial
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the completion of enrollment in the pivotal Phase 3 MOTION study of vimseltinib in patients with tenosynovial giant cell tumor not amenable to surgery.
RHEA-AI
neutral